{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.8","upperLimit":"58.4","value":"49.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"}],"units":"Participants"}],"description":"DCR was defined as the percentage of participants with a best overall response of CR or PR or with a best overall response of SD sustained for at least 8 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Duvelisib PO BID at a starting dose of 75 mg for the first 2 cycles, followed by a mandatory reduction to 25 mg BID thereafter for those participants with CR, PR or SD, in 28-day cycles (dose determined in Optimization Phase).","id":"OG000","title":"Expansion Phase"}],"paramType":"NUMBER","populationDescription":"Modified Intent-to-treat (mITT): all participants who received at least one dose of study drug. Here, 'Overall Number of Participants Analyzed' signifies those participants who were evaluable for this outcome measure. As pre-specified, efficacy analysis using IRC assessment reported for the Expansion Phase only.","reportingStatus":"POSTED","timeFrame":"Up to 8 weeks","title":"DCR as Assessed by the IRC Using the Lugano Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}